drugset / Trial / NCT07661420
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase 1
Not yet recruiting
16 enrolled
University of Pennsylvania
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Timeline
- Start
- 2026-08-01
- Primary completion
- 2029-08-01
- Completion
- 2032-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 211At-MABG | Other / unclassified | 1 mbq/kg | Intravenous |
| Subject | 211At-MABG | Other / unclassified | 2 mbq/kg | Intravenous |
| Subject | 211At-MABG | Other / unclassified | 4 mbq/kg | Intravenous |